Technology
Health
Biotechnology

InVivo Therapeutics

$0.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0185 (2.80%) As of 1:22 PM EDT today
+$0.0185 (2.80%) Today

Why Robinhood?

You can buy or sell NVIV and other stocks, options, ETFs, and crypto commission-free!

About NVIV

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. Read More The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in 2005 and is headquartered in Cambridge, MA.

Employees
6
Headquarters
Cambridge, Massachusetts
Founded
2005
Market Cap
6.33M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
101.89K
High Today
$0.7051
Low Today
$0.65
Open Price
$0.65
Volume
26.81K
52 Week High
$2.75
52 Week Low
$0.61

Collections

Technology
Health
Biotechnology
Medical
Therapy
2015 IPO
US
North America

NVIV Earnings

-$3.34
-$1.85
-$0.37
$1.12
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.30 per share
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.